ストックスクリーナーアプリを入手
14.41
0.84%
0.12
アフターアワーズ：
14.25
-0.16
-1.11%
前日終値:
$14.29
開ける：
$14.255
24時間の取引高:
1.06M
Relative Volume:
0.73
時価総額：
$1.61B
収益：
$577.74M
当期純損益:
$-149.78M
株価収益率:
-10.29
EPS:
-1.4
ネットキャッシュフロー:
$-78.21M
1週間 パフォーマンス:
+11.45%
1か月 パフォーマンス:
+18.99%
6か月 パフォーマンス:
-14.68%
1年 パフォーマンス:
-50.33%
1日の値動き範囲:
$14.26
$14.62
1週間の範囲:
$12.96
$14.62
52週間の値動き範囲:
$10.70
$29.29
Novocure Ltd Stock (NVCR) Company Profile
NVCR を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
14.41 | 1.60B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
127.04 | 222.19B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.65 | 144.97B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
367.75 | 140.12B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
99.77 | 128.60B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.83 | 49.82B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | 開始されました | Ladenburg Thalmann | Buy |
| 2024-12-02 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-10-16 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 再開されました | JP Morgan | Neutral |
| 2023-08-28 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 開始されました | SVB Securities | Outperform |
| 2023-07-31 | アップグレード | Evercore ISI | Underperform → In-line |
| 2023-06-07 | アップグレード | Wedbush | Underperform → Neutral |
| 2023-05-16 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2023-01-06 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2022-11-29 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-08 | 開始されました | Loop Capital | Buy |
| 2022-02-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2022-01-20 | アップグレード | Truist | Hold → Buy |
| 2022-01-03 | アップグレード | Evercore ISI | Underperform → In-line |
| 2021-07-01 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-14 | ダウングレード | Wedbush | Neutral → Underperform |
| 2021-01-25 | 繰り返されました | Piper Sandler | Overweight |
| 2020-09-23 | 開始されました | Northland Capital | Outperform |
| 2020-09-18 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | ダウングレード | Truist | Buy → Hold |
| 2020-06-01 | 再開されました | Oppenheimer | Perform |
| 2020-05-01 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-04-09 | ダウングレード | Evercore ISI | In-line → Underperform |
| 2020-03-05 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-07-29 | アップグレード | SunTrust | Hold → Buy |
| 2019-07-26 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2019-07-26 | ダウングレード | Wedbush | Outperform → Neutral |
| 2019-03-20 | 開始されました | SunTrust | Hold |
| 2018-11-02 | ダウングレード | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 開始されました | Evercore ISI | Outperform |
| 2018-04-18 | 繰り返されました | Mizuho | Buy |
| 2018-02-23 | 繰り返されました | Mizuho | Buy |
| 2017-05-24 | アップグレード | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 繰り返されました | Wedbush | Outperform |
| 2016-01-19 | 開始されました | Barclays | Underweight |
| 2015-12-02 | 開始されました | Deutsche Bank | Hold |
すべてを表示
Novocure Ltd (NVCR) 最新ニュース
Voya Investment Management LLC Sells 64,539,786 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Why NovoCure Limited stock could be next big winnerChart Pattern Recognition & View Live Stock Forecasts Instantly - bollywoodhelpline.com
NovoCure (NVCR): Assessing Valuation After a Recent Rebound From Multi‑Month Lows - Yahoo Finance UK
NovoCure (NVCR): Exploring Valuation After a Recent Share Price Rebound - simplywall.st
Has NovoCure’s Tumor Treating Fields Progress Created a Value Opportunity After the 2025 Share Slump? - Yahoo Finance
Novocure (NVCR) Q2 2025 Earnings Call Transcript - AOL.com
NovoCure (NVCR) Q3 2024 Earnings Call Transcript - The Globe and Mail
First Week of February 2026 Options Trading For NovoCure (NVCR) - Nasdaq
How to hear Novocure’s CEO speak at the J.P. Morgan healthcare event - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
MACD Signal: How analysts rate NovoCure Limited stock todayTrend Reversal & Capital Efficient Trade Techniques - Улправда
How analysts rate NovoCure Limited stock todayCEO Change & Smart Money Movement Tracker - Улправда
CapEx per share of NovoCure Ltd. – MUN:038 - TradingView — Track All Markets
Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail
NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN
Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - simplywall.st
Marshall Wace LLP Sells 392,992 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance
NovoCure (NASDAQ:NVCR) Stock Price Up 7%Time to Buy? - MarketBeat
What is the fair value estimate for NovoCure Limited (038) stock in 2025Weekly Trade Report & Verified Stock Trade Ideas - Newser
Edgestream Partners L.P. Increases Holdings in NovoCure Limited $NVCR - Defense World
Is NovoCure’s 93% Five Year Share Price Slide Now Creating an Opportunity in 2025? - Yahoo Finance
NovoCure Limited $NVCR Shares Purchased by American Century Companies Inc. - MarketBeat
NovoCure stock rating reiterated at Buy by H.C. Wainwright amid CEO change - Investing.com Nigeria
NovoCure (NASDAQ:NVCR) Shares Gap DownShould You Sell? - MarketBeat
Can NovoCure's Tumor Treating Fields Redefine Cancer Care By 2026? - RTTNews
Novocure names Frank Leonard as new CEO, replacing Ashley Cordova By Investing.com - Investing.com Australia
How Investors Are Reacting To NovoCure (NVCR) CEO Transition as Frank Leonard Takes the Helm - simplywall.st
Novocure CEO Ashley Cordova resigns, Frank Leonard succeeds - TipRanks
Novocure (NVCR) Appoints New CEO Amid Leadership Change - GuruFocus
Novocure names Frank Leonard as new CEO, replacing Ashley Cordova - Investing.com India
Novocure Ltd Announces CEO Transition - TradingView
Novocure (NASDAQ: NVCR) elevates President Frank Leonard to CEO as Ashley Cordova resigns - Stock Titan
Novocure Appoints Company President Frank Leonard as Chief Executive Officer - Yahoo Finance
NovoCure (NASDAQ:NVCR) Stock Crosses Below 50-Day Moving AverageTime to Sell? - MarketBeat
Novocure (NASDAQ: NVCR) to Present at 37th Piper Sandler Healthcare Conference on Dec. 2 - Stock Titan
NovoCure Limited (NVCR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will NovoCure Limited stock attract more institutional investorsInsider Buying & Breakout Confirmation Trade Signals - newser.com
Novocure at Jefferies London: Expanding Horizons in Cancer Treatment By Investing.com - Investing.com South Africa
Tangible book value per share of NovoCure Ltd. – DUS:038 - TradingView
Published on: 2025-11-19 05:31:32 - newser.com
Will NovoCure Limited stock benefit from green energy trendsPrice Action & AI Forecasted Entry/Exit Points - newser.com
Novocure at Jefferies London: Expanding Horizons in Cancer Treatment - Investing.com India
Novocure Ltd (NVCR) 財務データ
収益
当期純利益
現金流量
EPS
Novocure Ltd (NVCR) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
1.20%
0.32%
大文字化:
|
ボリューム (24 時間):